Oxurion has received €1m ($1.09m) in funding from Atlas as part of a subscription agreement with Atlas totalling up to €20.8m ($25m).

The funds will be part of mandatorily convertible bonds issued by Oxurion, which will be subscribed by Atlas over two years, with €8.8m ($9.6mx) of this already invested.

Oxurion issued 40 convertible bonds with an 8% discounted conversion price, compared to the three-day lowest average volume-weighted average price (VWAP) for the last ten consecutive trading days from the conversion notice.

Oxurion plans to use these funds for the development programme of THR-149, a plasma kallikrein (PKal)-inhibitor for the treatment of diabetic macular oedema (DME). The drug is currently being evaluated in a randomised, multicentre, active-comparator Phase II trial (NCT04527107), with the comparator being Bayer/Regeneron’s Eylea (aflibercept). The topline results from the trial are expected in Q4 2023.

DME is a common complication of diabetes, which occurs due to the accumulation of excess fluid within the retina ultimately leading to blindness. In the US, 3.8% of adults with diabetes have DME, as per a published article.

As per GlobalData analysis, the DME market is expected to grow to $11.1bn by 2031. Longer-acting anti-vascular endothelial growth factor (VEGF) therapies such as Roche’s Susvimo, Kodiak Science’s KSI-301, and Bayer/Regeneron’s high-dose Eylea are expected to drive DME market growth.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Furthermore, drugs with novel mechanisms of action such as THR-149 and Unity Biotechnology’s UBX-1325 are expected to propel further DME market growth. GlobalData forecasts THR-149 to generate $237m in 2030.

GlobalData is the parent company of Pharmaceutical Technology.

THR-149 would face stiff competition in the market, with biosimilars of aflibercept, a commonly used treatment for DME, expected to hit the market soon. Johnson & Johnson’s aflibercept biosimilar is currently in a pre-registration phase.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now